Photocure
Photocure ASA is a Norwegian specialty pharma company that develops and sells pharmaceuticals and medical devices based on proprietary photodynamic technology. Photocure's strategy in cancer is to continue the commercialization of Hexvix for bladder cancer diagnostics, and continue the development of the cancer portfolio and out-license prior to phase III studies. This strategy is based on a strong platform of intellectual property in photodynamic therapy.
| Allmennaksjeselskap | |
| Traded as | OSE: PHO |
| Industry | Pharmaceutical |
| Founded | 1993 |
| Headquarters | Oslo, Norway |
Key people | Daniel Schneider (CEO), Jan Egberts (Chairperson of the board) |
| Products | Hexvix Cysview |
| Revenue | NOK 150 million [1] |
Number of employees | 70 |
| Website | www.photocure.com |
Pharmaceuticals
Hexyl aminolevulinate hydrochloride for diagnosis of bladder cancer.
gollark: People haven't managed anything better yet, yes.
gollark: Humans are kind of awful.
gollark: Do we REALLY want our AIs to try and be as accurate as possible to *humans*?
gollark: If you value them, you need to stay around to wipe them out.
gollark: However, what about OTHER possible intelligent species (or future humans of some sort)?
References
- Photocure Annual Report 2010 Archived 2012-03-15 at the Wayback Machine
External links
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.